Table 1 Clinicopathological features of the 87 patients
From: Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
Clinicopathological features | n = 87(%) |
|---|---|
Age (median year, range)* | 56 (47–65) |
Sex, n (%) | |
Male | 66 (75.9) |
Female | 21 (24.1) |
Tumor differentiation, n (%) | |
Well-/median-differentiated | 15 (17.2) |
Poorly differentiated/mucinous or signet ring cell carcinoma | 72 (82.8) |
Tumor location, n (%) | |
Upper body | 16 (18.4) |
Middle body | 27 (31.0) |
Lower body | 41 (47.1) |
Diffuse type | 3 (3.4) |
Pre-chemotherapy T stage, n (%) | |
T0–2 | 4 (4.6) |
T3–4 | 83 (95.4) |
Pre-chemotherapy N stage, n (%) | |
N− | 18 (20.7) |
N+ | 69 (79.3) |
Pre-chemotherapy TNM, n (%) | |
II | 41 (47.1) |
III | 44 (50.6) |
IV | 2 (2.3) |
Neoadjuvant chemotherapy regimen, n (%) | |
FOLFOX | 67 (77.0) |
XELOX | 15 (17.2) |
SOX | 4 (4.6) |
Lauren classification, n (%) | |
Intestinal | 30 (34.5) |
Diffuse | 49 (56.3) |
Mixed | 8 (9.2) |
Neural invasion, n (%) | |
Yes | 1 (1.1) |
No | 86 (98.9) |
Vascular invasion, n (%) | |
Yes | 12 (13.8) |
No | 75 (86.2) |
ypT stage, n (%) | |
T0–1 | 9 (10.3) |
T2–3 | 55 (63.2) |
T4 | 23 (26.4) |
ypN stage, n (%) | |
N0 | 39 (44.8) |
N1+N2 | 28 (32.2) |
N3 | 20 (23.0) |
ypTNM stage, n (%) | |
0+I | 16 (18.4) |
II | 40 (46.0) |
III | 31 (35.6) |
GHR, n (%) | |
≥ 50% | 44 (50.6) |
< 50% | 43 (50.8) |
GHR, n (%) | |
≥ 2/3 | 30 (34.5) |
< 2/3 | 57 (65.5) |
GHR, n (%) | |
≥ 90% | 15 (17.2) |
< 90% | 72 (82.8) |